Inhibrx Biosciences, Inc. (INBX): who owns it and who trades it
As of Nov 16, 2026, INBX insiders reported 5 open-market sales worth $279K and 19 purchases worth $6.3M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Kimberly Manhard (Director), with $279K. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Inhibrx Biosciences
From the latest filingsOverall: more buying than selling. Famous investors mostly sold. Funds and insiders mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns INBX
162 funds and institutions reported INBX shares worth $1.4B at the end of Q2 2026, about 98% of the company. The largest holder is Morgan Stanley with 9.0%.
Funds and institutions (13F) 98%Everyone else 2%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Morgan Stanley | 1.31M | 8.95% | $124M | +4% |
| Perceptive Advisors LLC | 1.30M | 8.88% | $123M | -10% |
| Sanofi | 1.16M | 7.93% | $110M | No change |
| Viking Global Investors LP | 1.12M | 7.69% | $106M | -22% |
| HighTower Advisors, LLC | 870,551 | 5.96% | $82.5M | No change |
| Bank of America Corp | 841,141 | 5.76% | $79.7M | +2474% |
| BlackRock, Inc. | 825,972 | 5.65% | $78.3M | +3% |
| Schonfeld Strategic Advisors LLC | 697,586 | 4.78% | $66.1M | +174% |
| State Street Corp | 640,458 | 4.38% | $60.7M | +16% |
| Vanguard Capital Management LLC | 492,477 | 3.37% | $46.7M | +1% |
| Woodline Partners LP | 400,892 | 2.74% | $38M | +4% |
| Capital Research Global Investors | 363,050 | 2.49% | $34.4M | -8% |
| Goldman Sachs Group Inc | 338,176 | 2.32% | $32M | +256% |
| PFM Health Sciences, LP | 308,385 | 2.11% | $29.2M | +1% |
| Sofinnova Investments, Inc. | 303,103 | 2.08% | $28.7M | -25% |
| Healthcare of Ontario Pension Plan Trust Fund | 271,700 | 1.86% | $25.7M | +59% |
| Parkman Healthcare Partners LLC | 256,950 | 1.76% | $24.3M | – |
| Geode Capital Management, LLC | 256,175 | 1.75% | $24.3M | +11% |
| First Turn Management, LLC | 164,783 | 1.13% | $15.6M | – |
| Millennium Management LLC | 147,200 | 1.01% | $13.9M | -55% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, INBX insiders reported $6.3M of open-market purchases and $279K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 14, 2026 | Mark Lappe | CEO | Purchase | 2,470 | $84.07 | $208K | Form 4 |
| Oct 14, 2026 | Mark Lappe | CEO | Purchase | 2,470 | $85.00 | $210K | Form 4 |
| Oct 14, 2026 | Mark Lappe | CEO | Purchase | 100 | $85.76 | $8.6K | Form 4 |
| Oct 14, 2026 | Mark Lappe | CEO | Purchase | 2,449 | $84.07 | $206K | Form 4 |
| Oct 14, 2026 | Mark Lappe | CEO | Purchase | 2,451 | $85.00 | $208K | Form 4 |
| Sep 28, 2026 | Mark Lappe | CEO | Purchase | 1,500 | $98.88 | $148K | Form 4 |
| Sep 28, 2026 | Mark Lappe | CEO | Purchase | 3,000 | $101.70 | $305K | Form 4 |
| Sep 25, 2026 | Mark Lappe | CEO | Purchase | 3,324 | $98.87 | $329K | Form 4 |
| Sep 25, 2026 | Mark Lappe | CEO | Purchase | 2,176 | $99.60 | $217K | Form 4 |
| Sep 23, 2026 | Jon Faiz Kayyem | Director | Purchase | 5,000 | $100.00 | $500K | Form 4 |
| Sep 16, 2026 | Jon Faiz Kayyem | Director | Purchase | 5,000 | $100.00 | $500K | Form 4 |
| Sep 15, 2026 | Kimberly Manhard | Director | Sale | 500 | $105.05 | $52.5K | Form 4 |
| Sep 14, 2026 | Kimberly Manhard | Director | Sale | 500 | $110.26 | $55.1K | Form 4 |
| Sep 11, 2026 | Kimberly Manhard | Director | Sale | 500 | $111.78 | $55.9K | Form 4 |
| Sep 9, 2026 | Kimberly Manhard | Director | Sale | 500 | $115.80 | $57.9K | Form 4 |
| Sep 8, 2026 | Kimberly Manhard | Director | Sale | 500 | $115.14 | $57.6K | Form 4 |
| Sep 8, 2026 | Jon Faiz Kayyem | Director | Purchase | 5,000 | $113.52 | $568K | Form 4 |
| Sep 8, 2026 | Douglas Forsyth | Director | Purchase | 2,500 | $114.65 | $287K | Form 4 |
| Sep 8, 2026 | Mark Lappe | CEO | Purchase | 500 | $108.24 | $54.1K | Form 4 |
| Sep 8, 2026 | Mark Lappe | CEO | Purchase | 9,681 | $112.28 | $1.1M | Form 4 |
| Sep 8, 2026 | Mark Lappe | CEO | Purchase | 1,219 | $111.88 | $136K | Form 4 |
| Sep 8, 2026 | Mark Lappe | CEO | Purchase | 5,895 | $99.29 | $585K | Form 4 |
| Sep 8, 2026 | Mark Lappe | CEO | Purchase | 6,605 | $100.64 | $665K | Form 4 |
| Sep 8, 2026 | Mark Lappe | CEO | Purchase | 1,100 | $107.12 | $118K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Mark Lappe | Chief Executive Officer, Director | $4.5M | – | Oct 14, 2026 |
| Jon Faiz Kayyem | Director | $1.6M | – | Sep 23, 2026 |
| Douglas Forsyth | Director | $287K | – | Sep 8, 2026 |
| Kimberly Manhard | Director | – | $279K | Sep 15, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
INBX short interest
Very high short interest. 23.0% of INBX shares are sold short: about 1 share in 4. Over the last 12 reports the number of shares short went up 16%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 3.39M INBX shares were sold short, 23.0% of the shares outstanding, down 0.8% from the report before. At the average daily volume of 339,064 shares, buying them all back would take about 10.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 3.39M | 23.03% | -1% | 339,064 | 10.0 |
| Oct 15, 2026 | 3.42M | 23.22% | -0% | 202,984 | 16.8 |
| Sep 30, 2026 | 3.43M | 23.32% | +1% | 290,359 | 11.8 |
| Sep 15, 2026 | 3.39M | 23.06% | +3% | 408,480 | 8.3 |
| Aug 31, 2026 | 3.30M | 22.41% | +3% | 317,496 | 10.4 |
| Aug 14, 2026 | 3.22M | 21.85% | -4% | 223,490 | 14.4 |
| Jul 31, 2026 | 3.34M | 22.87% | -3% | 213,594 | 15.6 |
| Jul 15, 2026 | 3.43M | 23.51% | -0% | 379,873 | 9.0 |
| Jun 30, 2026 | 3.45M | 23.60% | +4% | 347,713 | 9.9 |
| Jun 15, 2026 | 3.30M | 22.59% | +4% | 321,930 | 10.2 |
| May 29, 2026 | 3.18M | 21.77% | +8% | 341,252 | 9.3 |
| May 15, 2026 | 2.93M | 20.08% | +7% | 654,241 | 4.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Inhibrx Biosciences company events
Inhibrx Biosciences filed 12 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Sep 28, 2026.
- Sep 28, 2026AnnouncementShared information with investors. Filing
- Sep 8, 2026AnnouncementOf this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for… Filing
- Aug 13, 2026ResultsReleased financial results. Filing
- Jul 16, 2026AgreementInhibrx Biosciences, Inc., Oxford Finance LLC as collateral agent, and the other lenders party thereto, entered into a second amendment to the Loan and Security Agreement dated as of January 13, 2025, as amended by the First Amendment dated March 18, 2026, pursuant to which the Lenders expanded the… Filing
- Jun 15, 2026AnnouncementThe Company announced that the FDA has accepted for filing its BLA seeking approval of ozekibart for the treatment of patients with unresectable or metastatic conventional chondrosarcoma. Filing
- Jun 3, 2026VoteReported shareholder vote results. Filing
- May 14, 2026ResultsReleased financial results. Filing
- May 11, 2026AnnouncementInhibrx posted an updated copy of its corporate presentation to the “Investors” tab of its website at www.inhibrx.com. Filing
- Apr 21, 2026AnnouncementInhibrx posted an updated copy of its corporate presentation to the “Investors” tab of its website at www.inhibrx.com. Filing
- Mar 19, 2026ResultsReleased financial results. Filing
- Feb 23, 2026AnnouncementShared information with investors. Filing
- Dec 16, 2025AnnouncementOf this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Inhibrx Biosciences financials
Famous investors that hold INBX
5 of the 50 well-known investors we track reported holding INBX in their latest 13F filing. The largest position is Andreas Halvorsen's, worth $111M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Andreas Halvorsen · Viking Global Investors | Q3 2026 | 1.11M | $111M | 0.3% | -1% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 22,855 | $2.3M | 0.0% | New |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 16,673 | $1.7M | 0.0% | -36% |
| Israel Englander · Millennium Management | Q3 2026 | 10,642 | $1.1M | 0.0% | -93% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 8,542 | $855K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named INBX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 13, 2026 | Schonfeld Strategic Advisors LLC | 13G/A | 6.5% |
| Nov 13, 2026 | Schonfeld Strategic Advisors LLC | 13G/A | 6.5% |
| Oct 28, 2026 | BANK OF AMERICA CORP /DE/ | 13G/A | 2.4% |
| Oct 28, 2026 | BANK OF AMERICA CORP /DE/ | 13G/A | 2.4% |
Questions about Inhibrx Biosciences, Inc. (INBX) stock
Who owns the most INBX stock?
The largest reported owner of Inhibrx Biosciences, Inc. (INBX) is Morgan Stanley, with 9.0% of the company. In total, 162 funds and institutions reported holding INBX at the end of Q2 2026, together about 98% of the shares. See the largest owners.
Are INBX insiders buying or selling?
In the last 12 months, INBX insiders reported 19 open-market purchases worth $6.3M and 5 sales worth $279K. The latest trade was on Oct 14, 2026. See every trade.
What is the short interest in INBX?
As of Oct 30, 2026, 3.39M INBX shares were sold short, 23.0% of the shares outstanding, down 0.8% from the report before. At the average daily volume of 339,064 shares, buying them all back would take about 10.0 trading days (days to cover). See the history.
Which famous investors hold INBX?
5 of the 50 well-known investors we track reported INBX in their latest 13F filing, including Andreas Halvorsen, Ken Griffin, Steve Cohen. The largest position is worth $111M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.